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Summary 
The lymphocyte activation gene 3 (LAG-3), expressed in human activated T and natural killer 
(NK) cells, is closely related to CD4 at the gene and protein levels. We report here the initial 
characterization of the LAG-3-encoded protein.  We have generated two monoclonal antibodies 
after immunization of mice with a 30-amino acid peptide that corresponds to an exposed extra 
loop region present in the LAG-3 immunoglobulin-like first domain. The reactivity of these 
reagents is directed against LAG-3 since they recognize both membrane-expressed and soluble 
recombinant LAG-3 molecules produced in a baculovirus expression system. The two antibodies 
are likely to react with the same or closely related epitope  (termed LAG-3.1) exposed on the 
LAG-3 first domain extra loop,  as assessed in competition experiments on LAG-3-expressing 
activated lymphocytes. Cellular distribution analysis  indicated that the LAG-3.1 epitope is expressed 
on activated T  (both CD4 + and CD8 + subsets) and NK cells, and not on activated B cells or 
monocytes. In immunoprecipitation experiments performed on activated T and NK cell lysates, 
a  70-kD  protein  was  detected after  SDS-PAGE analysis. 45-kD  protein  species were  also 
immunoprecipitated. Both the 70- and 45-kD proteins  were shown to be N-glycosylated.  In 
Western blot analysis, only the former molecule was recognized by the anti-LAG-3 antibodies, 
demonstrating that it is LAG-3 encoded. These anti-LAG-3 antibodies were used to investigate 
whether the LAG-3 protein interacts with the CD4 ligands. By using a high-level expression 
cellular system based on COS-7 cell transfection with recombinant CDM8 vectors and a quantitative 
cellular adhesion assay, we demonstrate that rosette formation between LAG-3-transfected COS-7 
cells and human leukocyte antigen (HLA) class II-bearing B lymphocytes is specifically  dependent 
on LAG-3/HLA  class II interaction.  In contrast to CD4,  LAG-3 does not bind the human 
immunodeficiency virus gp120. This initial characterization  will guide further studies on the 
functions of this molecule, which may play an important role in immune responses mediated 
by T  and NK lymphocytes. 
W 
e have recently found (1) a novel member of the im- 
munoglobulin superfamily (IgSF)  2 (2), termed lym- 
phocyte activation gene 3 (LAG-3), that is selectively tran- 
scribed in human activated  T and NK cells. The LAG-3 cDNA 
1 Contributions of these authors were equivalent,  and their order should 
be considered arbitrary. 
2 Abbreviations  used in this paper: aa, amino acid; IgSF, immunoglobulin 
superfamily;  LAG-3, lymphocyte activation gene 3;  NS, nonspecific. 
encodes a 470-amino acid (aa) membrane protein with four 
extracellular IgSF domains. Analysis of the LAG-3-encoded 
aa sequence revealed  notable patches of identity with stretches 
of sequences found at the corresponding positions in CD4. 
For example, the very unusual  W  x  C  sequence is found 
in domains  2 and 4 of both LAG-3 and CD4,  while it is 
not present in an equivalent position in any other IgSF do- 
mains. In addition,  as in the CD4 structure (3), there are 
some internal sequence homologies in the LAG-3 molecule 
between domains 1 and 3, as well as between domains 2 and 
4, suggesting that LAG-3 has evolved  like CD4 by gene dupli- 
cation from a preexisting two-IgSF structure.  Furthermore, 
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LAG-3 locus (eight exons that span 6 kb) revealed that the 
position of the introns in the LAG-3 structure is very dose 
to that of CD4, and that both genes include an intron within 
the first IgSF domain (1). Finally, both genes are located on 
the distal part of the short arm of chromosome 12 (band p13.3 
for LAG-3; reference 1). Together, these structural consider- 
ations at the gene and protein levels supported the view that 
LAG-3 and CD4 are closely related and derive from a common 
four-domain evolutionary ancestor (1). LAG-3 and CD4 can 
therefore be regarded as evolutionary "first cousins" within 
the IgSF. 
A unique feature of the LAG-3 molecule is the presence 
of a 30-aa extra loop sequence in the first NH2 terminus Ig- 
like domain between B strands C  and C'. Such a long extra 
loop structure has not been described in IgSF molecules. We 
have postulated that this extra loop does not disrupt the core 
of the IgSF fold that consists of B strands A,  B, E and G, 
F, C,  and therefore may be exposed to the solvent outside 
the hydrophobic Ig fold (1). 
Based on this hypothesis, we have generated antibodies by 
immunizing animals with a 30-aa peptide corresponding to 
the extra loop aa sequence. These reagents recognize specifically 
both natural and recombinant LAG-3-encoded proteins and 
have been used to study the cellular distribution, the molec- 
ular structure,  and the biological function(s) of the LAG-3 
protein. In particular,  since CD4 has been previously shown 
to interact with HLA class  II molecules (4-8) and to be a 
receptor for HIV retroviruses (9, 10), we have examined the 
ability of the LAG-3 protein, transiently expressed in COS-7 
cells,  to bind  these ligands. 
Materiah  and Methods 
Cell Cultures.  PBMC were obtained from healthy donors by 
Ficoll-Hypaque density gradient centrifugation.  Activated T cells 
were generated by stimulating  PBMC at a cellular concentration 
of 2  x  106/ml with 2 t~g/ml PHA-P in the presence or the ab- 
sence of riD2 (250 U/m1). Activated B cells were generated by stim- 
ulation  of 2  x  106 PBMC/ml with 0.3%  (wt/vol) PWM. For 
monocyte activation, PBMC were first submitted to adherence in 
DMEM, 10% FCS on plastic flasks at 37~  Adherent cells were 
recovered in KPMI supplemented with 1% FCS and incubated over- 
night with 5 t~g/ml LPS at 37~ 
Long-term cultured IL-2-dq~endent clonal or polyclonal T cells, 
including  MBA8,  T2,  K2,  PH28,  1C1  (CD3 +  TCR-od~+), 
TH6-4,  BK (CD3 + TCR.-r/8+),  as well  as the NK cell lines 
F55IIIE5 and SIB5 (CD3-CD56+), were obtained from healthy 
donors and cultivated in the presence of rII.-2 on a feeder layer of 
irradiated EBV-transformed  B ceils (LAZ 388) as previously  described 
(11, 12). Spodopterafrugiperda insect cells (SO cells) and COS-7 cells 
were cultivated following  standard protocols. 
mAbs and Recombinant  gp120 Protein.  The reactivity of the mAbs 
was studied by indirect immtmofluoresomce, and samples were ana- 
lyzed on an Elite Epics cytometer (Coulter Electronics, Inc., Hia- 
leah, FL). 5,000 cells were analyzed in each sample. The mAbs 
used in these studies were anti-NKTa, which recognizes a TCR- 
c~/B donotypic determinant  (13), anti-CD3 (OKT3), anti-CD4 
(OKT4), anti-CD8 (OKT8), anti-CD71  (OKT9) (Ortho Diag- 
nostics,  Karitan,  NJ), anti-CD56  (NKH1), anti-CD25  (Ib2R1) 
(Coulter Immunology),  and an anti-CD2  (XC3) produced in our 
laboratory (unpublished data). The binding of these antibodies were 
detected with either fluorescein- or PE-conjugated goat anti-mouse 
antibodies. The CD4-specific mAb OKT4E was provided by P. Rao 
(Johnson Pharmaceutical  Research Institute,  Raritan,  NJ).  The 
HI.A-DR-specific D1.12 mAb (14) was a gift  from  K.  Accolla 
(Ludwig Institute  for Cancer Research, Lausanne, Switzerhnd). 
The 9.49 mAb (Coulter Immunology) is specific  for the three HLA 
class II isotypes (15), 25.3.1 (Immunotech,  Marseille, France) for 
LFA-1 and CDlla, and 8F5 for ICAM-1 (16). Purified soluble recom- 
binant gp120 was kindly provided by M. P. Ki6ny and J. p. Lecocq 
(Soci6t6 Trans#ne,  Strasbourg,  France). 
Expression of  LAG-3 Recombinant Proteins.  A variety of eukary- 
otic genes, including CD4 (17), have been expressed in Slmioptera 
frugiperda insect ceils infected with a recombinant Autografa califor- 
nica nudear polyhedrosis virus (AcMNPv), and the corresponding 
recombinant proteins have been shown to be functionally, antigen- 
ically, and  biochemicaUy similar to  their  natural  counterparts 
(reviewed in reference 18). In the present experiments, a membrane 
as well as a soluble LAG-3 recombinant protein were produced using 
a baculovirus expression system, as described  previously for the LAG- 
1 protein (19). Briefly, the first construction,  designated LAG-3C 
(the  complete  coding  region  of LAG-3),  included  a  1,620-bp 
Eco47III-BgllI fragment derived from the LAG-3 cDNA sequence, 
termed FDC (1), which was inserted into the BamHI site of the 
pVL941 vector. The second construction,  designated LAG-3S, in- 
cluded an 1,106-bp Eco47III-BamHI  fragment  of sequence FDC 
and corresponds therefore to the first three Ig-like domains of LAG-3 
(aa 1-363). Insect SD cells were cotransfected with both the corre- 
sponding  recombinant  vector  (LAG-3C/pVL941  or  LAG- 
3S/pVL941) and the Autographa californica wild-type baculovirus ge- 
home (AcMNPv). After in vivo recombination,  virus was recov- 
ered from the SD supematant  and purified by limiting  dilution 
using the FDC sequence probe. 
The 1,620-bp Eco47III-BgllI FDC fragment was also cloned into 
the CDM8 eukaryotic expression vector (gift from B. Seed, Mas- 
sachusetts General Hospital, Boston, MA) at the BstXI sites after 
addition of BstXI linkers (Invitrogen, San Diego, CA). SmaU-scale 
DNA preparations of transformants in Escherichia coli MC1061/p3 
were digested by Sad to determine the correct orientation  of the 
cloned fragment. One done in the reverse orientation, termed GAL, 
was used as a negative control.  Trausfection of COS-7 cells were 
performed by the DEAE-dextran  method as previously described 
(8). For flow cytometry analysis on an Elite Epics, transfected cells 
were detached from plates with I mM EDTA in PBS and stained 
with the purified 17B4 mAb at 2 t~g/ml, and with a 1:50 dilution 
of FITC-conjugated goat antibody to mouse Igs (Nordic, Tilburg, 
The Netherlands). 
For the immunoprecipitation  analysis, COS-7 cells were trans- 
fected with the CDM8-LAG-3 plasmid by electroporation  using 
a Cdlject apparatus (Eurogentech,  Liege, BE). COS-7 cells were 
electroporated (200 V, 1,500 I~F, and infinite shunt resistor) with 
30 ~g/ml of plasmid in PBS at  107/ml. 
Producaon of  Anti-LAG-3 Antibodies.  A 30-aa peptide (GPPAAA- 
PGHPLAPGPHPAAPSSWGPILP1LP,  Y) designated 208B, which 
includes the extra loop protein sequence (1), was synthesized and 
coupled at its NH2 terminus  to the tetanus anatoxin carrier pro- 
rein. Rabbit immunizations were performed by injecting subcutane- 
ously 200/~g of 208B-coupled peptide resuspended in CFA. Boost 
injections in IFA were administrated at 4-wk intervals. Biozzi mice 
were immunized  by an initial intraperitoneal  injection  of 50/~g 
of 208B peptide in CFA, followed by injections on days 15, 30, 
and 50 in IFA. On day 70, mice were boosted via intravenous in- 
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immunized splenocytes were fused with NS1 HAT-sensitive my- 
eloma cells. 
Hybridoma  supernatants  reactive on  both  LAG-3 surface- 
expressing SD ceils and PHA-activated T cells (PHA blasts) were 
selected by indirect immunofluorescence  and subsequently  subcloned 
in HAT medium supplemented with 10% FCS. The 17B4 mAb 
(IgG1) was purified from the hybridoma supernatant on protein 
A-Sepharose CL-4B Fast Flow column (Pharmacia LKB, Uppsala, 
Sweden). 
The fine specificity of the anti-LAG-3 mAbs was determined 
by incubating at 4~  a nonsaturating dilution of the mAb with 
different concentrations of  either the 30-aa 208B peptide or a 28-aa 
LAG-3-unrelated peptide (termed nonspecific [NS]), followed by 
indirect immunofluorescence on PHA blasts. 
Western Blot Analysis.  Cell lysates or supernatants were ana- 
lyzed on a 10% polyacrylamide  gel and proteins were transferred 
to a 0.1-/~m nitrocellulose membrane using a MilliBIot-SDE dec_ 
troblotting apparatus (Miilipore, Bedford, MA). Antibody-reactive 
proteins were revealed according to the enhanced chemilumines- 
cence kit (Amersham International, Amersham, UK). Briefly, the 
membrane was incubated with the specific  antibody for 2 h at room 
temperature. The membrane was subsequently washed and then 
incubated for 1 h with a second antibody, either a peroxidase goat 
anti-mouse IgG (H+L) (Nordic) or peroxidase-conjugated  swine 
anti-rabbit  Igs (Dako, Glostrup, Denmark). The membrane was 
then washed and incubated for 1 min in a solution containing the 
detection reagent and autoradiographed. 
Immunoprecipitation of the Antigens.  Cell surface labeling using 
12sI was performed by a standard lactoperoxidase  method (20), and 
immunoprecipitations were carried out as previously  described (21). 
Briefly, cell pellets were resuspended in 1 ml of lysis buffer at pH 
7.2 containing 10 mM sodium phosphate, 1% triton X-100, 0.15 
M NaC1, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 1 mM PMSF, 
1 mg trypsin inhibitor, 1 mM iodoacetamide, and 0.1% sodium 
deoxycholate. Extensive preclearings were carried out and specific 
immunoprecipitations were performed sequentially with antiactin 
(an IgG1 kindly given by Dr. Haynes, Duke University, Medical 
Center, Durham, NC), anti-NKTa (an IgG1 used as negative con- 
trol),  17B4 (IgG1), and finally the XC3 anti-CD2 mAb. All the 
mAbs were coated to protein G-Sepharose beads and incubations 
with cell lysates were performed overnight at 4~  After washing 
the beads in lysis buffer, samples were eluted by boiling in SDS 
sample buffer in the absence or in the presence of 5% 2-ME, and 
analyzed in 10% SDS-PAGE under nonreducing or reducing con- 
ditions. Gels were stained with coomassie  blue, dried, and autora- 
diographed at  -80~ 
N-Deglycosylation Treatment of Glycoproteins.  After autoradio- 
graphic detection, the immunoprecipitated labeled proteins were 
excised, eluted, and lyophilized. The recovered material was re- 
hydrated in 10/~1 of 0.5% SDS buffer and denaturated by boiling 
for 4 min. Digestion with 0.2 U of N-glycosidase F (PNGase-F; 
Boehringer, Mannheim, Germany) was carried out overnight at 
37~  in a 40 #I buffer (pH 7.5) containing 250 mM sodium phos- 
phate,  10 mM EDTA, 10 mM 2-ME, and 1%  NOG (n-Octyl 
B-D-glucopyranoside). Cleavage products were resuspended in an 
equal volume of SDS sample buffer containing 5% 2-ME and ana- 
lyzed by SDS-PAGE. 
B Lymphocyte Adhesion to Transfected COS Cells.  Rosette for- 
mation between transfected COS cells and B lymphocytes  has been 
described in detail (8). Briefly, 5  x  10  ~ B lymphocytes were in- 
cubated for 1 h at 37~  with a COS cell monolayer in 12-well 
plates, 48 or 72 h after transfection with the recombinant LAG-3- 
and GAL-CDM8  vectors, and then washed five  times. After rosette 
formation, COS cells  were stained with an indirect immunoperox- 
idase method, as described (8), using the LAG-3-specific  17B4 an- 
tibody. Observation was done under a light microscope. Rosette 
quantification was expressed as the percentage of LAG-3-positive 
cells that have retained five B lymphocytes or more. Inhibition of 
rosettes was performed by preincubating cells for 30 rain with 
different  concentration of  mAbs. Incubation of  Raji cells  with anti- 
HLA-class II antibodies was done on cells fixed  by incubation with 
0.5% paraformaldehyde  for 10 rain at room temperature, followed 
by a two-time extensive washing in PBS and a 30-min incubation 
in DMEM 10% FCS. Rosettes were allowed to form in the pres- 
ence of the inhibitors. Results are expressed as the rosette inhibi- 
tion percentage of two or more experiments +  SD, calculated as 
follows: 100x [1- (% rosette with inhibitor/% rosette without in- 
hibitor). 
Results 
Generation of Anti-LAG-3  Antibodies.  Rabbits and mice 
were immunized with the tetanus toxoid-coupled 208B pep- 
tide (see Materials and Methods), whose sequence is derived 
from the extra loop of the LAG.3 Ig-like first domain (1). 
Two murine hybridoma supernatants,  designated 17134 (IgG1) 
and 4F4 (IgM), were selected  upon their reactivity in im- 
munofluorescence assays on AcLAG-3Cv (for A.  californica 
LAG.3C recombinant virus)-infected Sf9 cells (Fig. 1 A) and 
their lack of binding to either noninfected Sf9 cells or wild- 
type AcNPv-infected SD ceils (data not shown). A polyclonal 
rabbit antiserum (anti-208B)  raised against the 208B peptide 
was also reactive with AcLAG-3Cv-infected SD cells, while 
the preimmune serum (PI)  was not (Fig.  1 A). 
Both monodonal (17B4 and 4F4) and polyclonal (anti-208B) 
anti-LAG-3 antibodies were tested for their ability to recognize 
a soluble recombinant LAG-3 protein (LAG-3S) corresponding 
to  the  three  NH2  terminus  Ig-like  LAG-3  domains.  As 
shown by Western blot analysis of AcLAG.3Sv-infected Sf9 
ceil supernatant, they recognized a 43-kD protein band (Fig. 
1 B, lanes 2, 3, and 5). The translation of the 352-aa recom- 
binant LAG-3S protein should result in a 38-kD molecule; 
this size difference may derive from the addition of N-glycans 
by the SD insect ceils (22). Together, these data demonstrated 
that immunization with the 208B peptide has allowed the 
generation of anti-LAG.3-specific reagents. 
Initial experiments showed that both the 17134 and 4F4 
mAb reacted with PHA-activated PBMC (data not shown). 
The fine specificity of 17B4 was assessed in competition ex- 
periments using the 30-aa 208B peptide and a 28-aa LAG-3 
unrelated peptide (termed NS).  Preincubation of the 17134 
mAb  with a  300-nM  concentration of the  208B  peptide 
abrogated 17134 binding to PHA blasts (data not shown). 
Anti-LAG-3 mAb competitive binding to PHA blasts indi- 
cated that ceil preincubation with saturating amounts of 17B4 
abrogated 4F4 binding (data not shown). Together, these data 
confirmed that both antibodies recognize specifically the extra 
loop segment of the LAG.3 Ig-like first domain and showed 
that they are likely to react with the same or a closely related 
epitope, provisionally termed LAG.3.1. 
Cellular Distribution of tile LAG-3.1 Epitop~  The kinetics 
329  Baixeras  et al. Figure  1.  Reactivity of anti-LAG-3 antibodies. (A) Expression of LAG-3 
on AcLAG-3Cv-infected SD cells detected by indirect immunofluorescence. 
Cells  were  incubated  with  either  anti-NKTa,  17B4, 4F4  plus  goat 
anti-mouse serum or rabbit antiserum (anti-208B), preimmune rabbit serum 
(PI) plus goat anti-rabbit serum.  Histograms represent log10 red fluores- 
cence intensity versus cell numbers.  (B) Western blot analysis of AcLAG- 
3Sv-infected  Sf9 cell supernatant collected at day 6 postinfection. The transfer 
membrane was incubated with anti-NKTa (lane 1),  4F4 (lane 2),  17B4 
(lane 3), preimmune rabbit serum (lane 4), or anti-208B rabbit antiserum 
(lane 5). 
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Figure  2.  Kinetics of LAG-3.1 
epitope expression.  PBMC were 
stimulated by PHA and analyzed 
by indirect immunofluorescence 
with either 17B4 (A), anti-CD25 
(I),  or anti-CDT1  (0) mAbs. 
Figure  3.  Phenotypic analysis of PBMC-activated cells by indirect im- 
munofluoreseence. (A and B) Double-color analysis  of PHA-activated PBMC 
(A) or PWM-activated PBMC (B). x-axis shows log10 green fluorescence 
intensity obtained with FITC goat anti-mouse serum specific for the cor- 
responding antibody isotype (for each antigen), y-axis shows  logl0 red 
fluorescence intensity obtained with phycoerythrine goat anti-mouse serum 
specific for the corresponding antibody isotype (for each antigen). (C and 
D) Tonsil cells (C) and LPS-activated monocytes (D) analyzed by indirect 
immunofluorescence.  Histograms represent the number of cells versus the 
intensity of green fluorescence on a logarithmic scale. CD71 and CD25 
are used as activation markers for tonsil cells and monocytes (47), respectively. 
of LAG-3.1 epitope expression on PBMC was studied by in- 
direct immunofluorescence from day 0 to 8 after PHA acti- 
vation. Other activation antigens such as CD25 (IL-2R) and 
CD71 (transferrin receptor) were assessed in parallel (Fig. 2). 
At day 0, PBMC do not express the LAG-3.1 epitope. 17B4 
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at day 1, peaked at day 2 with >60% of the cells being posi- 
tive, decreased progressively until day 8 (Fig. 2), and became 
virtually undetectable at day 11 (data not shown). Restimu- 
lation of PHA blasts at day 11 by addition of either II.-2 (25 
and 250 U/ml), II.-4 (2.5 and 25 U/ml), or IFN-'t (10 and 
1,000 U/ml) indicated that only Ib2 (at 250 U/ml) was able 
to reinduce the expression of the LAG-3.1 epitope (data not 
shown). 
A  series of long-term cultured IL-2-dependent donal or 
polyclonal T  ceils,  including MBA8,  T2,  K2,  PH28,  1C1 
(CD3 + TCK-ot/~+),  TH6-4,  BK (CD3 + TCK-3d~+),  as 
well  as  the  NK  cell  lines  F55IIIE5  and  SIB5  (CD3- 
CD56+),  were tested and all found to express (at varying 
density) the LAG-3.1 epitope (data not shown). Conversely, 
a series of transformed cell lines did not express the LAG-3.1 
epitope:  T  cells  (PEEK,  HSB2,  REX,  CEM,  JURKAT, 
MOLT-4),  B  cells  (LAZ388,  LAT_A61, RAJI,  RAMOS, 
DAUDI, E418), and nonlymphoid cells (K562, FIb60, U-937, 
KG-1)  (data not shown). 
Taking advantage of the 4F4 mAb IgM isotype, coexpres- 
sion by day 2 PHA blasts of the LAG-3.1 epitope and other 
molecules (CD4, CD8, CD3, CD56, or CD25) was studied 
by double-color immunofluorescence analysis. As shown in 
a representative experiment (Fig. 3 A), the LAG-3.1 epitope 
was expressed on a majority of CD3 + (63% of them being 
LAG-3+), CD25 + (53%), CD4 + (58%),  or CD8 + (60%) 
lymphocytes. Approximately 3% of the PHA blasts expressing 
LAG-3.1 were CD3-.  An equivalent fraction was CD56 + . 
It is therefore likely that the corresponding cells were acti- 
vated CD3-CD56 + NK lymphocytes. Together, these re- 
suits show that the LAG-3 molecule is present on a majority 
of activated T  (CD4 + or CD8 +) ceils and on some NK cells 
at day 2  after PHA activation. 
The LAG-3.1 epitope was not found on resting B ceils (data 
not shown) nor on cultured (PWM-stimulated) peripheral 
blood B ceils (Fig.  3 B) expressing the CD20 molecule; in 
these experiments the expression of CD71 (transferrin receptor) 
was used as a control for cell activation. The LAG-3.1 epi- 
tope was not found in tonsils (Fig. 3 C), where a large frac- 
tion of the B cells constitutively express CD71,  in resting 
monocytes (data not shown), or LPS-activated monocytes (D). 
Together, these results confirm (1) that LAG-3 is selectively 
(i.e.,  T  and NK ceils as opposed to B ceils and monocytes) 
expressed on a large fraction of activated PBMC. 
Biochemical Characterization of  the LAG-3 Protein.  Immu- 
noprecipitations were performed on 12SI-labded day 2 PHA 
blasts, as well as on the IL,2-dependent NK clone, $1B5, which 
exhibited a higher LAG-3.1 epitope expression, as shown by 
immunofluorescence analysis (Fig. 4 A). SDS-PAGE analysis 
of the 17B4 immunoprecipitates from PHA blasts (Fig. 4 B, 
lane b) and $1B5 ceils (C, lane b) resolved in nonreducing 
conditions a 42-45-kD doublet band in addition to the 70-kD 
LAG-3 molecule. Under reducing conditions, the doublet band 
appeared as a  single 45-kD  species  (Fig.  4,  B  and C,  lane 
e). Extensive predearing of the lysates with antiactin mAb- 
coupled beads could rule out a possible contamination with 
Figure 4.  Immunoprecipitation  of  the LAG-3  protein  from  PHA blasts 
or SIB5 lysates. (A) LAG-3.1 epitope expression  on PHA blasts or SIB5 
cells as detected  by indirect immunofluorescence.  Histograms represent 
the number  of  cells  versus  intensity  of  fluorescence  on a logarithmic  scale. 
(B and C) SDS-PAGE  analysis  of  the LAG-3  protein  after  immunoprecipi- 
ration with 17134. PHA bhsts (B) or $1B5 cells (C) were t2sI labeled  and 
lysates  were  submitted  to immunoprecipitation  followed  by analysis  in SDS- 
PAGE under nonreducing  (NK) and reducing  (K) conditions. Immuno- 
precipitations  were  performed  using  anti-NKTa  (lanes  a and d), 17134  (lanes 
b and e), or anti-CD2 (lanes c and f). 
actin molecules. Immunoprecipitation positive and negative 
controls were performed by using anti-CD2 (lanes c andj~ 
and anti-NKTa (lanes  a  and d) mAbs, respectively. 
When PHA blast lysates were boiled in the presence of 
0.5% SDS, 2 mM DTT (or with SDS alone; data not shown) 
before immunoprecipitation with 17B4, only the 70-kD pro- 
tein was detected in SDS-PAGE (Fig. 5 A, lane 2), suggesting 
that the 70-kD protein but not the 45 kD proteins, is LAG-3 
encoded. Western blot analysis (Fig.  5 B) of LAG-3 + PHA 
blasts (lane 2) and $1B5 (lane 3) lysates confirmed the pres- 
ence of a similar 70-kD protein reactive with 17B4. This pro- 
tein was not detected in LAG-3- PBMCs (lane 1), E418 (an 
EBV-transformed B ceil line; lane 5), and U937 (lane 6) 1y- 
sates. Additional bands (68 and 60 kD; Fig. 5 B, lanes 2 and 
3) reactive with 17B4 might correspond to immature, par- 
tially glycosylated forms of the LAG-3 protein since the ex- 
pected molecular mass of the 470-aa LAG-3 protein back- 
bone is  51 kD  (1). 
Together, the results of the immunoprecipitation experi- 
331  Baixeras  et al. Figure  5.  (tl) Immunoprecipitation in denaturing conditions and SDS- 
PAGE analysis. 12SI-labeled  PHA blast lysates were boiled in 1% SDS, 2 
mM DTT, and subjected to immunoprecipitation with either anti-NKTa 
(lane I) or 17B4 (lane 2). (B) Western blot analysis of T or NK cell lysates 
using 17B4. Samples included: PBMC (lane I), PHA blasts (lane 2), SIB5 
cells (lane 3), AcLAG-3S-infected Sf9 cells supernatant (lane 4;  added as 
a positive control), E418 cell line (lane 5),  U937 cell line (lane 6). 
ments performed on activated T and NK cell lysates indicate 
that LAG-3 is likely to be noncovalently associated to one 
or several  45-kD molecule(s). One cannot exclude, however, 
that a LAG3.1 epitope-like structure may be present in a la- 
bile form (i.e., not recognized after denaturation) on distinct 
protein(s)  migrating at 45 kD in SDS-PAGE analysis. Fur- 
ther studies using reagents reacting with other segments of 
the LAG-3 protein will help  to solve these questions. 
Immunoprecipitation  of LAG-3-transfected COS-7 cell ly- 
sates with 17B4 revealed a major band of 68-70 kD in both 
nonreducing and reducing conditions (Fig. 6, lanes 2 and 4). 
An additional 52-55-kD immunoprecipitated band was de- 
tected and may correspond to an immature form of  the LAG-3 
protein (in these experiments,  a 30% COS-7 cell mortality 
was observed before 12si labeling) or to the association with 
a molecule distinct from that observed in activated T  and 
NK lymphocyte lysates. 
The two proteins (70 and 45 kD) immunoprecipitated from 
PHA blast lysates were extracted from the gel and indepen- 
dently submitted to N-glycosidase-F treatment. Reduction 
in size was observed for both species from 70 to 60 kD (Fig. 
7, lanes I and 2) and from 45 to 40 kD (lanes 3 and 4), indi- 
cating that molecules are glycosylated. The difference seen 
between the apparent mass of LAG-3 (60 kD) after N-gly- 
cosidase-F treatment and the predicted molecular mass of the 
mature protein backbone (51 kD) may be related to incom- 
plete N-deglycosylation  (four potential  N-linked glycosyla- 
tion sites in the LAG-3 sequence) or to other posttransla- 
tional  modifications. 
B Lymphocyte Adhesion to LAG-3.transfected COS Cells.  We 
used the high-level expression cellular system based on COS-7 
cell transfection with recombinant CDM8 vectors (23). This 
system has proved to be the most convenient to study binding 
of transiently expressed  wild-type and mutant CD4 with low 
affinity to HLA dass II and with high affinity to gp120 (8, 
24, 25). Transfections of COS-7 cells were performed in par- 
a11e1 with the CDM8-LAG-3 and CDM8-CD4 recombinant 
vectors. Cell surface expression, rosette formation with class 
II-bearing B lymphocytes, and gp120 binding were assayed. 
A  LAG-3 insert  cloned in the reverse orientation, termed 
CDM8-GAL, was used as negative control. 
As shown by flow cytometry analysis with 17B4 (Fig. 8 
A), 30-40%  COS-7 calls assessed on day 3 were found to 
express LAG-3 specifically COS ceils transfected with the 
reverse  construction GAL were not reactive with 17B4. Adhe- 
sion of the HLA class II-expressing Burkitt lymphoma line, 
Figure 6.  SDS-PAGE  analysis  of 
LAG-3 immunoprecipitated from trans- 
fected COS-7 cells. 12SI-labded LAG-3- 
transfected  COS-7 cell lysate was sub- 
mitted to anti-NKTa (lanes 1 and 3) or 
17B4 (lanes 2 and 4) immunoprecipita- 
tions. The immunocomplexes were ana- 
lyzed under nonreducing (NR) and re- 
ducing conditions (R). 
Figure 7.  N-Glycosidase-F 
treatment of the proteins immu- 
noprecipitated with  17B4. Both 
17B4-reactive proteins (70 and 45 
kD) were isolated independently 
and subjected to deglycosylation. 
Samples were analyzed by SDS- 
PAGE under reducing conditions: 
70-kD LAG*3  protein sham cleaved 
(Lane I) or N-Glycosidase-F  cleaved 
(lane 2); 45-kD LAG-3-associated 
protein sham (lane 3) or N-Gly- 
cosidase-F cleaved (lane 4); CD2 
protein sham- (lane 5) or N-gly- 
cosidase-F cleaved (lane 6). 
332  The Lymphocyte Activation Gene 3 Protein Figure 8.  Transient membrane  expression of LAG-3 in COS-7 cells and 
rosette formation between LAG-3-expression COS cells and B lympho- 
cytes expressing HLA class II molecules. (,4) Flow cytometry analysis of 
anti-LAG-3 17134  mAb binding  to COS cells transfected with the recom- 
binant CDM8-LAG-3 vector (LAG). The CDMS-GAL construct, as de- 
scribed in Materials and Methods, was used as a negative control (GAL). 
(B) Specific  adhesion of the HLA class II-positive,  Raji (arrows), but not 
of the HLA class II-negative, RJ2.2.5,  B lymphocytes to COS cells that 
express LAG-3, as detected by immunoperoxidase staining  with the 17134 
mAb. 
Raji, occurred only with LAG-3-exTressing COS cell (23  _ 
3%, n =  26), as detected by immunoperoxidase  staining with 
the 17B4 antibody (Fig. 8 B, arrows). No rosettes were ob- 
served with the I-ILA class II-negative mutant of Raji, RJ2.2.5 
(26)  (Hg.  8 B). COS cells transfected with the GAL con- 
struct did not form rosettes with Raji (data not shown). Ro- 
settes of Raji cells formed with LAG-3-  and CD4-positive 
(not shown) COS cells were morphologically  indistinguish- 
able. A series of cells expressing high levels of HLA class II 
antigens (Daudi, the EBV-transformed  cell lines E418, and 
ALF, the latter deriving from an LFA-l-negative immuno- 
deficient patient; reference 27) were found to form rosettes, 
while a series of class II-negative cells, K562, HSB2, BCH 
(28), and the TC line derived from a HLA class II-immuno- 
deficient patient (29),  did not (data  not shown). Together 
these results suggested that rosette formation was induced 
by the interaction of HLA class II and LAG-3  molecules. 
Rosettes between LAG-3-positive COS cells and Raji were 
specifically  inhibited in a dose-dependent manner by the LAG- 
3-specific 17B4 mAb (Fig. 9 A) and by two antibodies specific 
for HLA class II molecules: the monomorphic anti-HLA- 
DR mAb D1.12 (14) and the 9.49 mAb specific for the three 
HLA class II isotypes (15) (Fig. 9 B). Since anti-class II anti- 
bodies are known to induce aggregation of Raji B lympho- 
cytes, as the result of activation of LFA-l-dependent (30) or 
-independent (31) cell adhesion pathways, it raised the possi- 
bility that aggregation might interfere with the inhibitory 
properties of these antibodies. Raji cells were fixed with 0.5% 
paraformaldehyde before incubation with anti-class II anti- 
bodies. This treatment did not modify antibody binding to 
Raji (data not shown) and suppressed the aggregation pro- 
cess. In these conditions both anti-class II mAbs specifically 
inhibited the rosette formation (Fig.  9 B). The 9.49 mAb 
induced stronger rosette inhibition than D1.12,  indicating 
that HLA class II isotypes other than DR (i.e., DQ and DP) 
may interact with LAG-3, as described for CD4 (5). In con- 
trast, no inhibition was observed with the isotype-matched 
(IgG1) anti-CD4 mAb, OKT4E (Fig. 9 A), which is a po- 
tent inhibitor of rosettes between CD4-positive COS cells 
and Raji,  as previously described (8),  nor with  the anti- 
ICAM-1 mAb, 8F5 (16), and the anti-LFA-1 CDlla-specific 
mAb, 25.3.1 (Fig. 9 B), which are known to inhibit strongly 
cell adhesion mediated by LFA-1/ICAM-1 interactions.  Simi- 
larly,  the HLA dass I-specific mAb, W6.32 (32),  did not 
induce rosette inhibition (data not shown). These results dem- 
onstrate that cellular  adhesion is directly dependent upon 
specific LAG-3/HLA class II interaction. 
Since LAG-3  and CD4 are closely related, we have also 
examined the ability of the LAG-3 protein to bind the HIV 
gp120 protein.  In contrast to CD4,  binding of iodinated 
recombinant HIV gp120 to LAG-3-transfected  COS cells, as 
measured by a sensitive radioimmunoassay (24), was unde- 
tectable  (data  not shown). 
Discussion 
We have generated two anti-LAG-3 mAbs after mice im- 
munization with a 30-aa  peptide coupled at its NH2 ter- 
minus to tetanus toxoid. These reagents recognize specifically 
both membrane expressed and soluble recombinant LAG-3 
molecules produced in a baculovims expression system. The 
two antibodies are likely to react with the same or a closely 
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Figure 9.  Specific  binding  inhibition  of  class  II-bearing 
B tymphocytes  to LAG-3-positive  COS cells.  ~nt  con- 
centrations of antibodies were incubated 30 min before 
rosette formation  with LAG-3-transfected  COS cells (a), 
or with Raji  B lymphocytes  (b). Antibody  to LAG-3  was 
17B4 (am); to CD4, OKT4E ([-1); to HLA-DK, D1.12 
(O); to HLA-DK,  -DOo and -DP, 9.49 (Q); to ICAM-1, 
8F5 (&); and to LFA-1  CD11a, 25.3.1 (A). Rosettes  were 
allowed  to form  in the presence  of  the inhibitors  and quan- 
titated, as described (8). Results  are expressed as the ro- 
sette inhibition  percentage  of two or more experiments 
+ SD, as described  in Materials and Methods.  Antibody 
amount is expressed as -logs (dilution  ratio) indicated  as 
the number of 1/logs increasing  dilutions, when used as 
ascitic fluids (b). 
related epitope, provisionally termed LAG-3.1, exposed on 
the extra loop segment of the LAG-3 Ig-like first domain. 
Using these antibodies, we demonstrate here that a 70-kD 
molecule carrying the LAG-3.1 epitope is selectively expressed 
on the surface of activated T and NK cells as an "inte~i~ediate" 
activation antigen (33). Note that in Northern blot analysis, 
LAG-3 mRNA expression could not be clearly detected be- 
fore day 3 in PHA-stimulated lymphocytes (1). 
Peptide immunization may lead in some instances  to the 
generation of antibodies reacting with the native form of the 
corresponding protein (34). The present series of experiments 
show that two murine mAbs (17B4 and 4F4)  as well as a 
rabbit antiserum generated by peptide immunization are able 
to recognize the native LAG-3-encoded protein in immu- 
no  fluorescence assays. The generation of such antibodies may 
have been facilitated by the structure of the immunizing pep- 
tide, given its length (30 aa) and the fact that it includes 10 
prolines that are known to favor the induction of protein- 
reactive antibodies (35). In any case, the present results confirm 
that at least an epitope (LAG-3.1)  on the extra loop is ex- 
posed to the solvent on the surface of the LAG-3 Ig-like first 
domain (1). 
Since LAG-3 and CD4 genes have been considered to de- 
rive from a common evolutionary ancestor (1), initial studies 
on the LAG-3 biological function(s) have been designed to 
investigate whether CD4 and LAG-3 share common ligands: 
HLA class II antigens and HIV gp120. The inability of LAG-3 
to bind HIV gp120 could be expected because of the limited 
amino acid conservation (4/18 residues) with the CD4 gp120 
binding site and because it seems purely fortuitous that HIV 
has subverted the human CD4 molecule (and not the routine 
or the rat CD4) for its use (36). To analyze potential LAG-3/ 
HLA class II interactions, we used a quantitative cellular adhe- 
sion assay (8), based on the transient expression upon trans- 
fection of high levels of the LAG-3 protein by COS-7 cells. 
We were able to demonstrate the formation of rosettes be- 
tween LAG-3-transfected COS-7  cells  and HLA class  II- 
bearing B lymphocytes, which is specifically dependent on 
LAG-3/class II interaction as shown in blocking experiments 
using 17B4 and anti-dass II mAbs. 
These observations raise the question of the respective lo- 
calization of the class II binding sites for LAG-3 and CD4. 
We (8, 24, and unpublished data) and others (25) have pro- 
posed that the HLA class II and gp120 binding sites (Fig. 
10, arrows) were largely overlapping on CD4. On the other 
hand, using a different functional assay, others have proposed 
that both sites were separable  (37-39),  defining three key 
residues (Fig. 10, arrowheads) within exposed loops from CD4 
.,A  ......  B ......  C,.. 
LAG-3  VPVVWAQEGAPAQLPCSPTIPLQDLSLLRRAGVTWQHQPDSGPPAAAPGHPLAPGPHPAA  60 
hCD4  KKVVLGKKGDTVELTCTA~Q  .......  KKSIQFHWKNSN@  ....................  33 
,.A ......  B...  ￿9  ..C.. 
￿9 ..C'  ......  C".  .....  D .......  E .....  F. 
LAG-3  PSSWGPRPRRYTVLSVGPGGLRSGRLPLQPRVQLDERGRQRGDFSLWLRPARRADAGEYR 
hCD4  ..........  IKILGNOGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYI 
..C'.  I  .C".  ..D.  I  ...E  ......  F, 
￿9 ,.G  ........  A .......  B ......  C.., 
LAG-3  AAVHLRDRALSCRLRLRLGQASMTASPPGSLRASDWVILNCSFSRPDRPASVHWFRNR~ 
hCD4  CEVEDQKEEVQLLVFG  ......  LTANSDTHLLQGQSLTLTLE-SPPGSSPSVQCRSPRGK 
￿9 ..  ~ .....  G ..........  A .....  B .....  C., 
120 
83 
....  D ........  E .......  F ........  G... 
LAG-3  GRVPVRESPHHHLAESFLFLPQVSPM-DSGPWGCILTYRDGFNVSIHYNLTVLGL 
hCD4  NIQ ..........  OGKTLSVSQ-LELQDSGTWTCTVLQN~KKVEFKI-DIVVLAF 
..C'  ............  E .....  F ....  ￿9  .....  G .... 
180  Figure  10.  Alignments  of LAG-3 and human CD4 
amino acid sequences in domains 1 and 2. Identities  (*), 
13 a  similarities  (o), and gaps (-). The dotted  lines above and 
under the sequences indicate the positions of putative or 
determined  B strands  of LAG-3  and CD4 (48, 49), respec- 
2a4  tively.  The putative HLA class II binding  sites on CD4 
are marked by arrows (24, 25) and closed arrowheads 
179  (37-39). 
334  The Lymphocyte  Activation Gene 3 Protein domains I and 2, and located on the sheet opposite the gp120 
binding site.  None of these CD4 putative class II binding 
sites are conserved in LAG-3 (Fig. 10), suggesting that different 
LAG-3 regions might be involved in this function. This could 
be expected since the sequence similarity in human CD4 and 
LAG-3 domains 1 and 2 is only 17%, excluding the LAG-3 
30-aa extra loop, which has no equivalent in CD4. Template 
modeling together with site-directed mutagenesis will help 
towards a better definition of the class II binding sites. 
The demonstration that LAG-3 and CD4 proteins share 
a common ligand (i.e., HLA class II antigens) is of great im- 
portance to design further investigations for determining the 
function of this molecule. In vitro HLA class II-dependent 
cellular responses, such as mixed lymphocyte cultures, vari- 
dase (a mixture of streptokinase/streptodornase antigens; ref- 
erence 40), or OKT3 (41) -induced proliferations were studied 
in the presence of purified anti-LAG-3 mAb (17B4) or con- 
trol  antibodies.  The  addition  of 17B4  had  no  effect on 
[3H]TdR incorporation by proliferating lymphocytes in these 
assay systems when compared with control antibodies (data 
not shown). The absence of inhibition of HLA class II-de- 
pendent cellular responses by 17134 may relate to the com- 
plexity of cellular interactions known to involve other mole- 
cules expressed on activated lymphocytes (e.g., CD4/HLA 
class II, LFA-1/ICAM-1, or CD2/LFA-3). In addition, these 
initial experiments designed to assess primary in vitro stimu- 
lation might be inappropriate to detect inhibitory effects of 
anti-LAG-3  mAb because cells  are already committed to 
proliferate when the LAG-3 protein is expressed at the cell 
surface. In this respect, studies will have to test whether LAG- 
3 +-activated T  cells may be inhibited in secondary or sub- 
sequent class  II-dependent responses.  Similarly, CD4-  T 
lymphocytes mediating class II-restricted regulatory or effector 
functions have been occasionally characterized (42-46), and 
studying such infrequent cell types would represent a favorable 
experimental situation to assess LAG-3/class II interaction 
functions. 
LAG-3 may be effective in contributing to the stabiliza- 
tion of activated T cell interactions with macrophages, den- 
dritic cells, or activated B cells, which are known to express 
high numbers of  dass II molecules on their surface. The present 
results, which show that LAG-3 is expressed on activated 
CD4-T cells, suggest that this molecule may also stabilize 
cell-cell  contacts in T  cell responses that are not restricted 
by a TCR/peptide/class II interaction (e.g., class I-restricted 
CD8 + TCR-odfl + and most TCR-7/~ + cells). In addition, 
the demonstration of the expression of LAG-3 on activated 
NK lymphocytes, which are generally known as cells  ex- 
pressing a "non-MHC-requiring cytotoxicity;' suggests that 
it may also be of interest to consider a potential contribution 
of MHC class II molecules in these TCR-independent cyto- 
toxic reactions. 
In conclusion, the potential role of LAG-3/HLA class II 
interactions in the development of lymphocyte effector func- 
tions,  in the regulation of immune responses, and during 
thymic ontogeny will have to be assessed in light of the present 
findings. 
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